Immunotherapy Poised to Move Forward Into Stage III NSCLC – OncLive
OncLive |
Immunotherapy Poised to Move Forward Into Stage III NSCLC
OncLive In September 2017, at the annual European Society for Medical Oncology (ESMO) Congress, researchers presented positive data from a phase III trial of durvalumab (Imfinzi) in patients with stage III NSCLC.4,5 Durvalumab is an inhibitor of programmed … |
